Caster Semenya was defiant in every way at what very well could be her last 800 meter race.
Her raised fist at the start. Her unstoppable victory. And with her reply Friday to the big question of whether she will now submit to new testosterone regulations in track and field and take hormone-reducing medication.
“Hell no,” the Olympic champion from South Africa said.
Semenya responded to her defeat in a landmark court case against track and field’s governing body two days earlier with a resounding win in a place where she’s done nothing but win the last four years — over two laps of the track.
She won the 800 meters at the opening Diamond League meeting of the season in Doha, Qatar, with a meet record of 1 minute, 54.98 seconds. It was her fourth-fastest time ever. The only person ahead of her at any time during the race was the pacemaker.
Semenya’s nearest challenger, the Olympic silver medalist Francine Niyonsaba, was nearly three seconds and about 20 meters behind her — barely in the picture. Ajee Wilson of the United States was third.
It was Semenya’s first 800 meter race this year and first since losing her case against the IAAF this week.
“Actions speak louder than words,” Semenya told the BBC. “When you are a great champion, you always deliver.”
But Semenya’s four-year dominance over two laps — Friday’s win was her 30th straight in the 800 continuing a run that started in late 2015 — may now be at an end.
Ended not by another competitor, but by new regulations set to come into effect Wednesday. They require the South African star and other female athletes with high levels of natural testosterone to medically lower them to be eligible to compete in events ranging from 400 meters to the mile.
Semenya failed to overturn those rules in her appeal to the Court of Arbitration for Sport.
Now, her career appears to be at a crossroads: Does she take medication to lower her testosterone? The medication will likely inhibit her athletic performance and could blunt her dominance. Or does she switch events and run in long-distance races not affected by the regulations?
She was emphatic when she told reporters after Friday’s race that she wouldn’t take the medication.
“That’s an illegal method,” she said.
But Semenya also didn’t give a clear idea of what she would do next. She said she wouldn’t move up to the 5,000 meters and she definitely wouldn’t retire.
“God has decided my career, God will end my career,” she said in the BBC interview. “No man, or any other human, can stop me from running. How am I going to retire when I’m 28? I still feel young, energetic. I still have 10 years or more in athletics.
“It doesn’t matter how I’m going to do it. What matters is I’ll still be here. I am never going anywhere.”
Semenya’s comments may foreshadow an appeal against the CAS ruling, aimed first at allowing Semenya to defend her 800 title at the world championships, also in Doha, in September and October while not taking the hormone-suppressing drugs.
But, if she keeps her promise not to lower her testosterone, there is a chance that Friday was the last time that Semenya runs in the 800, where she is a double Olympic and a three-time world champion, and arguably the best female athlete to run the distance in 40 years.
Her career, however, seems destined to be overshadowed by the testosterone debate, which has the potential for implications far beyond her own results.
Semenya gave away little on the track to indicate it might be her last race at the distance. She raised her right fist when announcers introduced her before the race.
She was presented with a bunch of flowers and tossed them to the crowd at the end. She then gave a thumbs-up to fans, flashed a brief smile, and walked off the track.
More AP sports: https://apnews.com/apf-sports and https://twitter.com/AP_Sports
The Western Journal has not reviewed this Associated Press story prior to publication. Therefore, it may contain editorial bias or may in some other way not meet our normal editorial standards. It is provided to our readers as a service from The Western Journal.
Truth and Accuracy
We are committed to truth and accuracy in all of our journalism. Read our editorial standards.